https://www.selleckchem.com/pr....oducts/zunsemetinib.
Corticosteroid therapy at the time of ICU admission [odds ratio (OR) 0.07] and cancer progression (OR 0.09) was independently associated with continuation of anticancer therapy. The mortality rate 1year after ICU admission was 73%. On multivariate analysis, continuation of anticancer therapy (OR 0.18) and Karnofsky performance status on admission (OR 0.9 were independently associated with lower 1-year mortality. The presence of high-grade glioma is not sufficient to justify refusal of intensive care unit admission. Performance st
Like
Comment
Share
